-
公开(公告)号：US20120165310A1
公开(公告)日：2012-06-28
申请号：US13394534
申请日：2010-09-10
申请人： Bei Chen , Robin Alec Fairhurst , Andreas Floersheimer , Pascal Furet , Vito Guagnano , Jiang Songchun , Wenshuo Lu , Thomas H. Marsilje, III , Clive McCarthy , Pierre-Yves Michellys , Frederic Stauffer , Stefan Stutz , Andrea Vaupel
发明人： Bei Chen , Robin Alec Fairhurst , Andreas Floersheimer , Pascal Furet , Vito Guagnano , Jiang Songchun , Wenshuo Lu , Thomas H. Marsilje, III , Clive McCarthy , Pierre-Yves Michellys , Frederic Stauffer , Stefan Stutz , Andrea Vaupel
IPC分类号： A61K31/519 , A61K31/541 , C07D493/08 , A61K31/5377 , A61K31/554 , A61P19/00 , A61K31/5386 , C07D495/08 , A61P35/00 , A61P11/00 , A61P1/16 , C07D487/04 , C07D487/08
CPC分类号： C07D487/04 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2059 , A61K9/4858
摘要： The invention relates to compounds of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease.
摘要翻译： 本发明涉及式I化合物，其中取代基如说明书中所定义; 制备这些化合物的方法; 包含这些化合物的药物组合物; 诸如药物的化合物; 这种化合物用于治疗增殖性疾病。
-
公开(公告)号：US20110112096A1
公开(公告)日：2011-05-12
申请号：US13000999
申请日：2009-06-24
申请人： Thomas H. Marsilje , Wenshuo Lu , Bei Chen , Xiaohui He , Songchun Jiang , Kunyong Yang
发明人： Thomas H. Marsilje , Wenshuo Lu , Bei Chen , Xiaohui He , Songchun Jiang , Kunyong Yang
IPC分类号： A61K31/5377 , C07D403/12 , C07D413/14 , C07D401/14 , C07D409/14 , C07D405/14 , C07D403/14 , C07D417/14 , A61K31/506 , A61K31/496 , C12N5/071 , A61P35/00 , A61P31/00
CPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
摘要翻译： 本发明提供式（I）的新型嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶衍生物可用于治疗，改善或预防对胰岛素样生长因子（IGF-1R）或分泌性淋巴瘤激酶（ALK）的抑制作出反应的病症。
-
公开(公告)号：US20090075996A1
公开(公告)日：2009-03-19
申请号：US11995683
申请日：2006-07-14
申请人： Phillip B. Alper , Thomas Marsilje , Arnab Chatterjee , Wenshuo Lu , Daniel Mutnick , Michael Roberts , Yun He
发明人： Phillip B. Alper , Thomas Marsilje , Arnab Chatterjee , Wenshuo Lu , Daniel Mutnick , Michael Roberts , Yun He
IPC分类号： A61K31/5377 , C07D209/82 , C07D413/08 , A61K31/403
CPC分类号： C08J7/04 , C07D209/80 , C07D209/94 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D491/04 , C07D495/04 , C08J7/045 , C08J2369/00
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的TPO活性相关的疾病或病症的方法，特别是涉及血小板减少症的疾病或病症。
-
公开(公告)号：US20050014724A1
公开(公告)日：2005-01-20
申请号：US10849079
申请日：2004-05-19
申请人： Thomas Marsilje , Nathanel Gray , Tao Jiang , Wenshuo Lu , Shifeng Pan
发明人： Thomas Marsilje , Nathanel Gray , Tao Jiang , Wenshuo Lu , Shifeng Pan
IPC分类号： A61K20060101 , A61K31/195 , A61K31/216 , A61K31/397 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/675 , C07C323/63 , C07D205/04 , C07D207/12 , C07D211/32 , C07D241/04 , C07F9/22 , C07F9/28
CPC分类号： C07C323/32 , C07C317/32 , C07C2601/14 , C07D205/04
摘要： The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
-
公开(公告)号：US09440957B2
公开(公告)日：2016-09-13
申请号：US14405773
申请日：2013-06-05
申请人： Gerald Lelais , Robert Epple , Thomas H. Marsilje, III , Pierre-Yves Michellys , Matthew McNeill , Yun Long , Wenshuo Lu , Bei Chen , Badry Bursulaya , Songchun Jiang
发明人： Gerald Lelais , Robert Epple , Thomas H. Marsilje, III , Pierre-Yves Michellys , Matthew McNeill , Yun Long , Wenshuo Lu , Bei Chen , Badry Bursulaya , Songchun Jiang
IPC分类号： A61K31/55 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D411/14 , C07D413/14 , C07D417/14 , A61K31/4184 , A61K31/454 , A61K31/4545 , A61K31/551 , A61K31/553 , A61K45/06 , C07D401/04 , C07D413/04 , C07D471/04 , C07D513/04
CPC分类号： C07D401/14 , A61K31/4184 , A61K31/454 , A61K31/4545 , A61K31/55 , A61K31/551 , A61K31/553 , A61K45/06 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D513/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
摘要翻译： 本发明提供了可用于调节EGFR活性的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调的EGFR活性相关的病症的方法。
-
公开(公告)号：US08153671B2
公开(公告)日：2012-04-10
申请号：US11995683
申请日：2006-07-14
申请人： Phillip B. Alper , Thomas Marsilje , Arnab Chatterjee , Wenshuo Lu , Daniel Mutnick , Michael Roberts , Yun He
发明人： Phillip B. Alper , Thomas Marsilje , Arnab Chatterjee , Wenshuo Lu , Daniel Mutnick , Michael Roberts , Yun He
IPC分类号： A61K31/404 , C07D487/02
CPC分类号： C08J7/04 , C07D209/80 , C07D209/94 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D491/04 , C07D495/04 , C08J7/045 , C08J2369/00
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的TPO活性相关的疾病或病症的方法，特别是涉及血小板减少症的疾病或病症。
-
公开(公告)号：US20110257154A1
公开(公告)日：2011-10-20
申请号：US13172357
申请日：2011-06-29
申请人： Pierre-Yves Michellys , Wei Pei , Thomas H. Marsilje , Wenshuo Lu , Bei Chen , Tetsuo Uno , Yunho Jin , Tao Jiang
发明人： Pierre-Yves Michellys , Wei Pei , Thomas H. Marsilje , Wenshuo Lu , Bei Chen , Tetsuo Uno , Yunho Jin , Tao Jiang
IPC分类号： A61K31/397 , A61K31/506 , C07D239/48 , A61K31/505 , C07D413/14 , A61K31/5377 , C07D413/12 , C07D403/12 , A61K31/496 , C07D487/04 , A61K31/519 , A61K31/52 , A61P31/00 , A61P35/00 , C12N5/09 , C07D401/14
CPC分类号： A61K31/506 , A61K31/5377 , A61K45/06 , C07D213/74 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D451/02 , C07D453/02 , C07D471/04 , C07D473/16 , C07D487/04 , C07D487/08
摘要： The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
-
公开(公告)号：US07572811B2
公开(公告)日：2009-08-11
申请号：US10590618
申请日：2005-02-24
申请人： Shifeng Pan , Thomas Marsilje , Wenshuo Lu , Wenqi Gao , Nathanael Schiander Gray , Yun He , Yahua Liu , Yuan Mi , Yongping Xie
发明人： Shifeng Pan , Thomas Marsilje , Wenshuo Lu , Wenqi Gao , Nathanael Schiander Gray , Yun He , Yahua Liu , Yuan Mi , Yongping Xie
IPC分类号： A61K31/445 , C07D211/30
CPC分类号： C07D401/04 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/22 , C07D213/74 , C07D237/22 , C07D239/46 , C07D295/108 , C07D295/15 , C07D401/06 , C07D403/04 , C07D403/06 , C07D409/04 , C07D409/12 , C07D413/10 , C07D417/10
摘要： The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
摘要翻译： 本发明涉及免疫抑制剂，其生产方法及其用途和含有它们的药物组合物。 本发明提供了一类新颖的化合物，其可用于治疗或预防由淋巴细胞相互作用介导的疾病或病症，特别是与EDG受体介导的信号转导相关的疾病。
-
公开(公告)号：US20070203100A1
公开(公告)日：2007-08-30
申请号：US10590618
申请日：2005-02-24
申请人： Shifeng Pan , Thomas Marsilje , Wenshuo Lu , Gao Wenqi , Nathanael Gray , Yun He , Yahua Liu , Yuan Mi , Yongping Xie
发明人： Shifeng Pan , Thomas Marsilje , Wenshuo Lu , Gao Wenqi , Nathanael Gray , Yun He , Yahua Liu , Yuan Mi , Yongping Xie
IPC分类号： A61K31/675 , A61K31/495 , A61K31/454 , A61K31/453 , A61K31/40
CPC分类号： C07D401/04 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/22 , C07D213/74 , C07D237/22 , C07D239/46 , C07D295/108 , C07D295/15 , C07D401/06 , C07D403/04 , C07D403/06 , C07D409/04 , C07D409/12 , C07D413/10 , C07D417/10
摘要： The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
摘要翻译： 本发明涉及免疫抑制剂，其生产方法及其用途和含有它们的药物组合物。 本发明提供了一类新颖的化合物，其可用于治疗或预防由淋巴细胞相互作用介导的疾病或病症，特别是与EDG受体介导的信号转导相关的疾病。
-
公开(公告)号：US08519129B2
公开(公告)日：2013-08-27
申请号：US13000955
申请日：2009-06-24
申请人： Thomas H. Marsilje, III , Wenshuo Lu , Bei Chen , Xiaohui He , Christian Cho-Hua Lee , Songchun Jiang , Kunyong Yang
发明人： Thomas H. Marsilje, III , Wenshuo Lu , Bei Chen , Xiaohui He , Christian Cho-Hua Lee , Songchun Jiang , Kunyong Yang
IPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , A61K31/506 , A61P35/00
CPC分类号： C07D401/14 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
摘要翻译： 本发明提供新颖的嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶衍生物可用于治疗，改善或预防对胰岛素样生长因子（IGF-1R）或间变性淋巴瘤激酶（ALK）的抑制作出反应的病症。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.032 秒)
